|Bid||13.41 x 800|
|Ask||13.41 x 900|
|Day's Range||13.21 - 13.68|
|52 Week Range||10.30 - 20.92|
|Beta (5Y Monthly)||2.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.60|
Omeros Corporation (Nasdaq: OMER) ("Omeros"), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, announced today the full exercise and closing of the sale of 572,518 shares of common stock to the underwriter of its previously announced public offering pursuant to the underwriter’s option under the underwriting agreement to purchase additional shares of common stock. When combined with shares sold in the closing that occurred on December 9, 2019, Omeros sold an aggregate of 4,389,311 shares of common stock in the offering at $13.10 per share and the total gross proceeds to Omeros, before deduction of underwriting discounts and other estimated offering expenses, were approximately $57.5 million.
Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology 2019 Immuno-Oncology Congress, which is being held December 11-14, 2019 in Geneva, Switzerland.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...
Omeros Corporation (Nasdaq: OMER) ("Omeros"), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced that it has commenced a registered underwritten public offering of its common stock. In addition, Omeros has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering.
Shares of thinly-traded small-cap biopharma Omeros Corporation (NASDAQ: OMER) are advancing Wednesday following a positive readout from a pivotal Phase 3 study of its investigational asset narsoplimab. Omeros said the pivotal study that evaluated narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, or HCST-TMA, met the composite primary endpoint and the secondary endpoints. Narsoplimab is Omeros' lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2.
Shares of Omeros Corp. rallied 7% in morning trading on positive data for narsoplimab, its experimental therapy for a complication that can occur for patients undergoing stem cell transplants. Half of the patients who underwent treatment with narsoplimab in a trial met the Food and Drug Administration's response criteria. "The data from this trial form the efficacy basis of the application" to the FDA, Omeros CEO Gregory Demopulos said in a news release. Narsoplimab has been granted orphan drug and breakthrough therapy designations. Omeros stock has gained 40% year-to-date. The S&P 500 , in comparison, is up 24%.
Omeros Corporation (OMER) today announced positive data from its pivotal clinical trial of the company’s novel investigational complement inhibitor narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a frequently lethal complication of HSCT.
Omeros Corporation presented new GPR174 immuno-oncology data yesterday at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts.
Omeros Corporation (OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency enhances anti-tumor immune responses in animals. The studies were conducted in mouse models of melanoma and of colon carcinoma, each of which was modified to partially deplete regulatory T cells, a subset of immunosuppressive T cells. Partial depletion of regulatory T cells in mice creates a T-cell composition more similar to that in humans.
NEW YORK, NY / ACCESSWIRE / November 16, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ:OMER). Such investors ...
If you want to know who really controls Omeros Corporation (NASDAQ:OMER), then you'll have to look at the makeup of...
Omeros (OMER) delivered earnings and revenue surprises of 47.37% and 3.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Omeros Corporation today announced an upcoming presentation entitled “Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses” at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy, which is being held November 17 - 20, 2019 in Boston, Massachusetts.
Omeros Corporation (OMER) today announced that three of its scientists––Alexander Gragerov, Ph.D., associate vice president of research, George A. Gaitanaris, M.D., Ph.D., chief scientific officer, and Gregory A. Demopulos, M.D., chairman and chief executive officer––have been named as recipients of the 2019 Prix Galien Canada Research Award. The most prestigious award in the field of Canadian pharmaceutical research and innovation, it is referred to as the Nobel Prize of pharmaceutical research. Specifically, the technology allows high-throughput identification from drug libraries of functionally active compounds, or surrogate ligands, for “orphan” G protein-coupled receptors (GPCRs), which have no previously known ligands.
Omeros Corporation (OMER), today announced that the company will issue its third quarter 2019 financial results for the period ended September 30, 2019, on Tuesday, November 12, 2019, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally.
NEW YORK, NY / ACCESSWIRE / November 4, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Omeros Corporation ("Omeros" or "the Company") ...
Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (OMER). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. The investigation concerns whether Omeros and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Omeros Corporation (OMER) today announced that results of a prospective, controlled study showing that its FDA-approved ophthalmic drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% reduces use of the opioid fentanyl during cataract surgery while also reducing surgical pain were published today in the peer-reviewed journal Clinical Ophthalmology. The article, The Effect of Phenylephrine/Ketorolac Intracameral Solution 1%/0.3% on Pain and Opioid Use During Cataract Surgery, is authored by the study investigator Eric D. Donnenfeld, M.D., Clinical Professor of Ophthalmology at New York University and recent past president of the American Society of Cataract and Refractive Surgery. OMIDRIA is approved by FDA for prevention of miosis (pupil constriction) and for reduction in postoperative pain for adults and pediatric patients undergoing cataract or lens replacement surgery.
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
Omeros Corporation (OMER) today announced that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has issued a positive opinion for the company’s pediatric investigation plan (PIP) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab, also referred to as OMS721, is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2). Acceptance of the PIP paves the way for submission under the European Commission’s centralized procedure of a Marketing Authorization Application (MAA) for narsoplimab in the treatment of HSCT-TMA.